Standardized Lycium Chinense Fruit Extract Enhances Attention and Cognitive Function in Healthy Young People

Biomix75 enrolled

Overview

Lycium chinense fruit (LCF) is widely distributed in East Asia that has been used traditionally for anti-aging purposes. This study was performed to examine the effects of LCF on attention and cognitive function in healthy young people. An 11-week, double-blind, randomized, placebo-controlled, crossover trial was conducted.

The Computerized Neurocognitive function Test (CNT), the Korean version of the Attention-deficit/hyperactivity disorder (ADHD) Rating Scale-IV (K-ADHD-RS-IV), the Clinical Global Impression (CGI) rating scale, the Frankfurt Attention Inventory (FAIR), and resting-state electroencephalogram (EEG) were conducted before and after the experiment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

Standardized Lycium chinense Fruit Extract (LCF) capsulesDIETARY_SUPPLEMENT

All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).

Eligibility

Sex: ALLMin age: 14 YearsMax age: 24 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 14 and 24 years old * Male or female * Ability to understand the objectives of the study and agreed to abide by the required rules during the study. * If participants were aged between 14 and 20 years old, they and their parents had to provide informed consent. Exclusion Criteria: * Diagnosis of ADHD (any subtype) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria * Diagnosis of a developmental disorder * Pregnant or breastfeeding women and women with the possibility of getting pregnant * Gastrointestinal disease or history of gastrointestinal surgery, which might affect the absorption of study materials * Significant neurological (epilepsy, mental retardation, or stroke) or medical illnesses (diabetes, hypertension, or cardiovascular diseases), * Participation in other clinical studies during the four weeks preceding the start of the study * More than 1.5 times normal limit of ALT or AST.

Locations (1)

Biomix

Goyang-si, Gyeonggi-do, South Korea